Purpose: To evaluate the occurrence of complications following intravitreal injections (IVIs) performed in an outpatient clean room (OCR) equipped with the mobile laminar airflow device (LAF) Operio. Methods: This retrospective study analyzed the data of 10,016 IVIs performed in an OCR from April 2023 to November 2024. All information of each patient was registered, such as diagnosis, drug injected and any occurring complication or adverse events such as endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment (RRD), vitreous hemorrhages and elevated intraocular pressure. Results: From April 2023 to November 2024, 10,016 IVIs were performed in 1700 eyes of 1460 patients with the average age of 76.10 ± 12.37 years. The most representative diagnosis were Age-related Macular Degeneration (AMD) (47.60%), Retinal Vein Occlusion (RVO) (18.90%) and Diabetic Macular Edema (DME) (8.42%). Ten (4.24%) cases of ocular hypertensions were reported after dexamethasone implant whereas no cases of endophthalmitis or RRD were registered. Conclusions: The OCR equipped with Operio was easy to set up, safe regarding all IVI-related complications, first and foremost endophthalmitis, helpful in improving the management of IVIS, and allowed us to decongest the operating room for more complex surgeries.
Safety of intravitreal injections with the mobile laminar airflow device Operio after more than 10.000 injections / Fiore, T., De Santi, N., Bianchi, E., Cerquaglia, A., Lupidi, M., Tosi, G., Cagini, C.. - In: INTERNATIONAL OPHTHALMOLOGY. - ISSN 0165-5701. - 45:(2025). [10.1007/s10792-025-03485-7]
Safety of intravitreal injections with the mobile laminar airflow device Operio after more than 10.000 injections
Fiore T.Primo
;Cerquaglia A.;Lupidi M.;Cagini C.Ultimo
2025-01-01
Abstract
Purpose: To evaluate the occurrence of complications following intravitreal injections (IVIs) performed in an outpatient clean room (OCR) equipped with the mobile laminar airflow device (LAF) Operio. Methods: This retrospective study analyzed the data of 10,016 IVIs performed in an OCR from April 2023 to November 2024. All information of each patient was registered, such as diagnosis, drug injected and any occurring complication or adverse events such as endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment (RRD), vitreous hemorrhages and elevated intraocular pressure. Results: From April 2023 to November 2024, 10,016 IVIs were performed in 1700 eyes of 1460 patients with the average age of 76.10 ± 12.37 years. The most representative diagnosis were Age-related Macular Degeneration (AMD) (47.60%), Retinal Vein Occlusion (RVO) (18.90%) and Diabetic Macular Edema (DME) (8.42%). Ten (4.24%) cases of ocular hypertensions were reported after dexamethasone implant whereas no cases of endophthalmitis or RRD were registered. Conclusions: The OCR equipped with Operio was easy to set up, safe regarding all IVI-related complications, first and foremost endophthalmitis, helpful in improving the management of IVIS, and allowed us to decongest the operating room for more complex surgeries.| File | Dimensione | Formato | |
|---|---|---|---|
|
Fiore_Safety-intravitreal-injections-mobile_2025.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Tutti i diritti riservati
Dimensione
469.85 kB
Formato
Adobe PDF
|
469.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


